At A Glance
Pharma marketers can support more informed health journeys when patient and HCP messaging is relevant, privacy-forward, and optimized against meaningful outcomes. In this Ask the Expert conversation, Experian and DeepIntent discuss how health marketers can coordinate education, CTV, activation workflows, and measurement without entering private clinical decisions.Privacy-forward pharma media supports more informed healthcare journeys
Effective pharma marketing depends on reaching patients, caregivers, and healthcare professionals (HCPs) with useful information in appropriate, privacy-forward ways. The goal is to make relevant education easier to find, support more informed conversations, and help brands understand how media contributes across the health journey.
In this Ask the Expert session, Natalie Mancuso, SVP, Data Partnerships at DeepIntent, joins Sheila Wirick, who leads the health team at Experian, to discuss how to craft patient and HCP campaigns, privacy-safe activation workflows, connected TV (CTV), and measurement approaches built for pharma.
Why should your media plan start with understanding the patient and provider
The patient-and-provider journey should inform your media plan, as treatment decisions in pharma are increasingly informed, personal, and patient-driven. With more health information available than ever, patients are playing a more active role in understanding their options and participating in treatment conversations. As other industries become more customer-centric, pharma media planning needs to become more patient-centric.
“We’ve got patients who are more informed, more involved in their treatment decisions than ever. The accessibility of data and information and the ways we can consume it with just AI alone is so vast that if we’re not arming people with the right information in real time, we’re missing the boat.”
DeepIntentNatalie Mancuso, SVP, Data Partnerships
This means media should be aligned to where a patient or provider is in the decision journey and what they need at that moment. Early on, media may play an educational role by building awareness of a condition, symptom, or treatment category. Later, it may help support more specific questions, treatment consideration, access, affordability, or adherence.
The patient-provider conversation remains the key boundary. That exchange should stay private and clinically led. Media can play a valuable role before and after those moments by offering information that helps patients and providers feel more informed.
How can brands connect patient and HCP messaging responsibly?
It’s critical for agencies and brands to deliver relevant messaging to inform each stakeholder’s needs throughout the treatment journey, especially ahead of key clinical milestones. To execute this, brands must exercise privacy-forward activation, keeping patient and HCP identity, activation, and measurement paths separate, while using a common workflow layer to support the same brand goal.
Experian helps pharma marketers do this by acting as an independent, privacy-forward identity, data, and workflow layer. We bring together high-fidelity matching, governed onboarding, and non-clinical consumer context, so patient and HCP engagement can be activated more accurately across channels and connected to reporting.
The distinction is not only where each audience is reached. HCPs may be engaged in both professional and personal environments, but their needs are different from patients’. For example, an HCP may receive messaging about co-pay savings for eligible patients, while a patient may receive information about patient support programs. These are different messages for different audiences, but they ladder up to the same goal: informing both parties in a privacy-forward, relevant way.
Hear from Natalie Mancuso in our 2026 State of advertising report
In our 2026 State of advertising report, Natalie shares why identity serves as the connective infrastructure that links planning, activation, and measurement across connected TV (CTV), programmatic, commerce media, and walled garden environments.
What does privacy-forward activation look like in pharma?
Pharma brands often start with fragmented patient and HCP signals. Privacy-forward activation turns those inputs into usable audiences by first confirming that the data can be used, then translating identity in controlled environments that protect personally identifiable information through tokenization or other methodologies.
For DTC, that means building and matching audiences without relying on inferred health conditions from browsing behavior. For HCPs, it means connecting professional identity to verified sources in a way that supports activation and measurement. In a category shaped by HIPAA, state privacy laws, internal review, and consumer sensitivity, building privacy in from sourcing through activation is what makes responsible health media possible.
How can CTV play a more useful role in pharma?
CTV can play a more useful role in healthcare when it’s connected to a larger, privacy-forward plan and not treated as just an awareness channel.
DeepIntent connects CTV and digital exposure data using identity signals, such as National Provider Identifiers (NPIs), hashed email addresses, IP addresses, device IDs, and household signals, where permitted and reviewed. That identity layer helps support sequencing and suppression across streaming, endemic, mobile, and digital settings.
In practice, CTV can introduce targeted education or broad brand awareness, and later touchpoints can provide sequential information in the right channels. Instead of repeating the same message, brands can make pivots based on engagement and context.
“For us, it starts with identity and not panels. When we’re resolving CTV and digital exposures to the same person, we’re leveraging signals so that every touchpoint across streaming, endemic, and mobile is recognized as the same individual, not model lookalikes.”
DeepIntentNatalie Mancuso, SVP, Data Partnerships
For pharma, campaign performance should not be measured by reach alone. A stronger approach looks at whether sequenced engagement contributes to meaningful downstream signals, including:
- Prescription activity
- Provider engagement
- Referral patterns
- Patient compliance
- Adherence signals, where measurement is permitted
Why should messaging and reporting change in pharma?
Pharma campaigns are journeys with changing information needs. Reporting should guide the campaign optimization.
“If I’m launching into a market with a new class of drug, I’m asking what education needs to be put into the market – from both an HCP and a consumer standpoint – to build awareness?”
DeepIntentNatalie Mancuso, SVP, Data Partnerships
Clicks and website visits still have a place, but they can’t tell the full pharma story. DeepIntent processes data in real time, giving brands an up-to-date read on how media connects to campaign engagement. Campaign signals can help teams optimize audience logic, creative, channel mix, or sequencing during a live campaign.
Explore how privacy-safe pharma activation can make an impact
Experian brings marketing data and identity expertise for health marketing and DeepIntent adds pharma-specific activation experience. Together, we help brands connect patient and HCP strategies responsibly, with privacy built in from the start.
Watch the full video with our experts to hear Sheila Wirick and Natalie Mancuso discuss patient and HCP messaging, CTV, privacy-safe activation, and outcome measurement for pharma brands.
About our experts
Natalie Mancuso
SVP, Data Partnerships, DeepIntent
Natalie Mancuso is SVP, Data Partnerships at DeepIntent and a leader in health-focused AdTech and DSP strategy. With over 20 years of experience growing billion-dollar healthcare brands, she turns complex data into scalable, performance-driven solutions that keep marketers ahead of industry change.
Sheila Wirick
Director of Health Sales, Experian
Sheila Wirick is the Director of Health Sales at Experian with more than 20 years of experience in data and analytics. As Director of Health Sales at Experian Marketing Services, she collaborates with healthcare, pharmaceutical, and nonprofit organizations to apply data and insights that enhance customer retention, brand awareness, and acquisition. She is committed to helping organizations use data to deliver measurable results and meaningful impact.
FAQs
A pharma audience is activation-ready when patient or HCP inputs can be translated into usable audiences with the right accuracy, controls, interoperability, and destination readiness. For patient engagement, that may include privacy-safe cohort construction, caregiver logic, non-clinical enrichment and appropriate exclusion rules. For HCP engagement, it may include governed identity inputs such as NPI, specialty, practice location, professional address and other verified attributes where appropriate.
Pharma brands can sequence messages responsibly by giving each channel a clear role and using audience logic to maintain continuity. CTV and out-of-home can support awareness, social can reinforce the message, search can capture active research and point-of-care or rep-triggered channels can support decision moments. The workflow should preserve separation between patient and HCP identity strategies.
Pharma marketers should measure whether media connects to outcomes such as audience quality, prescription activity, qualified HCP engagement, verified delivery, referral patterns, therapy starts or adherence signals where permitted. These outcomes often depend on partner-enabled workflows, clean rooms, and aggregated outputs rather than direct end-to-end tracking.
Experian acts as an independent privacy-first identity, data, and workflow layer for pharma marketers. We help brands bring together identity, high-fidelity matching, governed onboarding, non-clinical consumer context, and partner interoperability so patient and HCP engagement can be activated more accurately across channels and connected more cleanly to partner-enabled measurement.
Latest posts
Tapad, part of Experian, partners with Flashtalking to create impactful attribution modeling strategy
Featured storiesPartnership Yields Increased Match and Connectivity Rate Through Tapad Graph, acquired by Experian March 27, 2018 — New York, N.Y. — Tapad, part of Experian, is reinventing personalization for the modern marketer and today announced the impactful results of its strategic partnership with Flashtalking, the leading global independent platform for ad delivery, unification and insights. Flashtalking is one of Tapad’s most engaged partners, using the Tapad Graph to unify cross-device engagement and identity-driven consumer behaviors for attribution modeling. The company leverages a unique identifier that, in conjunction with Tapad’s Graph, provides robust multi-touch attribution solution for its clients. This partnership has resulted in above-industry match and bridge rates for Flashtalking and its customers. Overall, the Tapad Graph yielded a 71 percent match rate with 41 percent of converters engaging on multiple devices, highlighting the importance of cross-device measurement. Tapad’s identity solutions provide Flashtalking with a more holistic view of global engagement. Flashtalking marries ad server log file data with the Tapad Graph to connect all interactions in the consumer journey. This enables Flashtalking to provide more accurate and impactful cross-device attribution, which ultimately enables better optimization. These achievements have led to recognition of Tapad and Flashtalking’s work by the I-COM Global Forum for Marketing, Data and Measurement. “Tapad allows us to understand user engagement across devices and platforms at both the household or individual user level, which is extremely beneficial when providing marketers with true path to conversion and attribution,” said Steve Latham, global head of analytics at Flashtalking. “Since our relationship began, we’ve successfully leveraged Tapad data to provide more accurate, actionable insights that have helped numerous brands achieve substantial gains in media effectiveness.” Flashtalking client Michael Lamontagne, SVP of analytics and CRM at 22squared says “We are big believers in using cross-device insights to improve our campaigns. Flashtalking has been a strategic partner in the pursuit of that goal. By incorporating the Tapad Graph, Flashtalking delivers powerful insights into user engagement and media attribution across browsers and devices. Of equal importance, their bundled solution makes it easy and efficient, saving our team countless hours of busy work.” Contact us today
Tapad, part of Experian, partners with Freckle IoT to enable cross-device offline attribution for brands
Featured storiesThe Tapad Device Graph™ Complements Freckle’s IoT Capabilities to Extend Scale and Precision of Audience Data New York, NY — December 6, 2017 — Tapad, part of Experian, is the leader in cross-device marketing technology and Freckle IoT, the global leader in multi-touch, offline attribution, today announced they are partnering to provide brands with a holistic and insightful view of their customers, in predefined locations in all global markets. Starting today Freckle IoT will be leveraging the Tapad Device Graph™ to supplement the company’s data set to offer brands more granular attribution data. Consumer’s online behavior is becoming more and more complex, with the average consumer owning three or more devices and 35 percent of consumers converting on a different device from the one on which they started their research. These interactions become even more complicated when considering how online interactions and media impact offline sales. The collaboration between Tapad and Freckle, which combines Freckle IoT’s persistent location data with Tapad’s proprietary cross-device technology, is an important step in empowering brands with the information they need to better understand how digital media, consumed across multiple devices, is impacting offline attribution. Using its opt-in, first-party data, Freckle IoT helps brands measure the effectiveness of their advertising by independently matching media spend to in-store visits. Tapad’s technology extends Freckle’s data-set by allowing brands to access additional deterministic and probabilistic data, at scale and across all devices, to analyze consumer behavior ahead of in-store purchase. “Combining our technology with Tapad’s identity-driven solutions was a natural fit for our business,” said Neil Sweeney, founder and CEO at Freckle IoT. “With our unbiased, agnostic measurement and Tapad’s precise and privacy-safe data set, we knew this partnership would be a strong complement to providing more effective results for the needs of our brand partners.” For more information on Freckle IoT’s measurement offerings, please visit www.freckleiot.com. Contact us today
Tapad, part of Experian, gathers momentum in EMEA with extensive growth across key markets
Featured storiesLondon – 24 November, 2017 – Tapad, part of Experian, is the leader in cross-device marketing technology and continues to broaden its reach across EMEA. The business today reported a 20 percent growth in the scope of its regional device graph, a data set used by organisations to map consumers to their devices, enabling better, more personalised cross-device marketing. This news complements Tapad’s recent expansion of its UK team with the hire of experienced solutions engineer, Davide Rosamilia. As the demand for cross-device technology solutions continues to grow around the globe, coupled with the emergence of regulations such as Europe’s General Data Protection Regulation (GDPR), Tapad is committed to offering suppliers the greatest level of insight without compromising consumer privacy. Since Tapad started licensing its proprietary Tapad Device GraphTM just over a year ago, demand for the company’s technology has experienced significant growth. New supply partnerships and proactive data sourcing have also meant an increase in devices across key markets, which contribute to the overall 20 percent growth of the EMEA device graph, including a 44 percent increase in the U.K., 47 percent in France, and 85 percent in Germany. “We’re continuing to invest heavily in growing our regional device graph, allowing us to better meet the needs of EMEA marketers as they strive to reach individuals with greater precision in some of the most tightly regulated marketplaces worldwide,” said Tom Rolph, VP EMEA, Tapad. “This year, we have also welcomed 10 new data suppliers whom we’ve helped to increase cross-device amplification, attribution and audience extension, helping to further set us apart in the marketplace and successfully expand our EMEA presence.” Available around the world, the Device Graph provides access to Tapad’s globally compliant and privacy-safe datasets across EMEA, APAC and the U.S., and offers deeper knowledge of consumer preferences, purchase intent, and conversion behaviors. “Tapad has shown a unique ability to adapt to the nuances of the local EMEA market and display impressive growth without sacrificing dedication to privacy,” said Alistair Hill, CEO and Co-founder at On Device Research. “When we started vetting technology vendors, we needed to be sure that we selected a partner that could offer compliant and privacy-safe datasets to operate within our stringent data standards. Tapad’s probabilistic solution offered us greater scale, greater device reach, and increased engagement without compromising on privacy.” Contact us today